Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Psoriasis

Psoriasis

Subtypes of Psoriasis

Plaque psoriasis 14 Erythrodermic psoriasis 1 Generalized pustular psoriasis 1 Inverse Psoriasis 1

37 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Psoriasis

289 trials tracked for Psoriasis: 148 in phase 3 or 4 and 52 with published results. The most-cited published study has 841 citations.

289Trials tracked
148Phase 3 & 4
0Recruiting
52With published results
Phase distribution
Phase 4 50 Phase 3 98 Phase 2 85 Phase 1 21 Other / NA 35
  1. Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis Completed · 841 cited
  2. Phase 4 Mechanism of Action Study for Psoriasis Completed · 722 cited
  3. Phase 3 Etanercept (Enbrel®) in Psoriasis - Pediatrics Completed · 388 cited
  4. Phase 3 A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis Completed · 377 cited
  5. Phase 3 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 299 cited
  6. Phase 3 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment Completed · 216 cited
Show 44 more trials
  1. Phase 3 An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 155 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 155 cited
  3. Phase 4 Vascular Inflammation in Psoriasis - Extension Study Completed · 148 cited
  4. Phase 4 Vascular Inflammation in Psoriasis Trial (The VIP Trial) Completed · 147 cited
  5. Phase 3 A Study in Japanese Participants With Moderate-to-Severe Psoriasis Completed · 132 cited
  6. Phase 3 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) Completed · 131 cited
  7. Phase 3 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis Completed · 87 cited
  8. Phase 3 Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis Completed · 87 cited
  9. Phase 3 Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis Completed · 82 cited
  10. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Completed · 82 cited
  11. Phase 3 A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis Completed · 81 cited
  12. Phase 3 A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis Completed · 71 cited
  13. Phase 3 A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) Completed · 69 cited
  14. Phase 3 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed · 56 cited
  15. Phase 3 A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab Completed · 56 cited
  16. Phase 3 Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy Completed · 56 cited
  17. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed · 55 cited
  18. Phase 3 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 54 cited
  19. Phase 3 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 54 cited
  20. Phase 3 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) Completed · 49 cited
  21. Phase 3 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp Completed · 48 cited
  22. Phase 4 Vascular Inflammation in Psoriasis - Apremilast Completed · 44 cited
  23. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 41 cited
  24. Phase 3 Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis Completed · 41 cited
  25. Phase 3 Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis Completed · 33 cited
  26. Phase 3 A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Completed · 29 cited
  27. Phase 3 A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis Completed · 27 cited
  28. Phase 3 The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis Completed · 27 cited
  29. Phase 3 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis Completed · 27 cited
  30. Phase 3 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis Completed · 26 cited
  31. Phase 4 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy Completed · 22 cited
  32. Phase 3 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Completed · 20 cited
  33. Phase 3 Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 20 cited
  34. Phase 3 An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age Completed · 18 cited
  35. Phase 3 Study of Secukinumab With 2 mL Pre-filled Syringes Completed · 18 cited
  36. Phase 3 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis Completed · 16 cited
  37. Phase 4 A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies Completed · 14 cited
  38. Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) Completed · 13 cited
  39. Phase 3 A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 12 cited
  40. Phase 4 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed · 10 cited
  41. Phase 3 A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Completed · 4 cited
  42. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea Completed · 3 cited
  43. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis Completed · 3 cited
  44. Phase 4 A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis Completed · 2 cited

Showing the 50 most-cited and recently-updated of 289 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Psoriasis: what the trials found

Secukinumab showed no significant difference in PASI 90 at week 28 compared to placebo (p=0.3857) but demonstrated a significant difference in PASI 75 over time (p=0.0300) 1. Risankizumab significantly improved PASI 90 and sPGA 0/1 at week 16 versus placebo (both p<0.001) 7. Deucravacitinib significantly improved DLQI 0/1, DLQI ≥4 reduction, and itch NRS at week 16 (p=0.0001 to p<0.0001) 14, and significantly improved scalp-specific outcomes (Ss-PGA 0/1, PSSI 90, scalp itch NRS) at week 16 (all p<0.0001) 16. Apremilast significantly improved DLQI ≥4 reduction and DLQI change at week 16 (p<0.0001) and BSA percent change (p=0.0085) 11. Tildrakizumab significantly improved quality of life (PGWB and DLQI) over time (p<0.001 to p=0.011) 10. Methotrexate showed significant improvement in biologic activity endpoints (p<0.05) and clinical endpoints (PASI 75: 67% vs 27%; PGA 0-1: 73% vs 27%) 3. Efalizumab resulted in 68% of patients achieving PGA good or better, with 11% rebound and 12.9% exacerbation 8; another trial reported 46% achieving PGA excellent or cleared at week 24 9. Tapinarof cream 1% led to 23% of patients achieving target lesion PGA clear/almost clear in head/neck 17 and 24% achieving intertriginous PGA clear/almost clear 18. Adalimumab showed no significant change in vascular inflammation or cardiometabolic biomarkers (p>0.05) 4. Apremilast showed no significant change in aortic vascular inflammation (p=0.612) or cardiometabolic markers (CRP p=0.617, ferritin p=0.083) 6. Tildrakizumab showed minimal change in coronary flow reserve (-0.03) and no significant correlation with skin severity (p=0.35) 13. Metaderm improved sPGA*BSA (53.06% vs 65.6%) and DLQI (52.88% vs 17.82%) 21. Apremilast improved nail psoriasis (mNAPSI mean percent change 64.1% at week 36, p=0.05) and nail pain VAS (-50.42%) 22. Secukinumab improved itch, pain, and PASI scores (change: 3, 2, 8 respectively) 15.

Recent results — preliminary, needs further review

  • Orticumab (phase 2, N=77) showed variable mean percent change in PASI across doses (-3.46 to -20.14) and low rates of PASI75/PASI50 (0-51%) and sIGA success (1 participant per group) 2.

For the clinician treating this condition

  • Risankizumab, deucravacitinib, and apremilast demonstrate significant improvements in skin clearance and quality of life measures.
  • Biologics like secukinumab and tildrakizumab also improve quality of life, though secukinumab's PASI 90 at week 28 was not significant.
  • Methotrexate remains effective for clinical endpoints, while apremilast shows benefit for nail psoriasis.
  • Cardiovascular outcomes with adalimumab, apremilast, and tildrakizumab did not show significant changes.

AI synthesis of 18 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia
Dermatology Meta-analysis
Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia Regional differences in health risks for hidradenitis suppurativa patients
This systematic review and meta-analysis examines the prevalence of hidradenitis suppurativa-associated comorbidities across North America, …
A meta-analysis reveals how hidradenitis suppurativa patients in North America, Europe, and the Middle East/Asia face different odds for dia…
May 1, 2026
Imsidolimab shows GPPPGA clearance in generalized pustular psoriasis flare at 4 weeks
Dermatology RCT
Imsidolimab shows GPPPGA clearance in generalized pustular psoriasis flare at 4 weeks A New Drug Clears Severe Skin Flares Fast
This phase 3 randomized controlled trial in 45 patients with a GPP flare found that a single intravenous dose of imsidolimab led to a higher…
A new medicine stops severe skin flares quickly without causing dangerous side effects for most patients
NEJM Evid Apr 28, 2026
Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps
Drug Pipeline Sys. Review
Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps Review of ginsenosides for skin conditions shows weak evidence and low absorption
This narrative review examines the use of ginsenosides for various skin conditions, including psoriasis, dermatitis, photoaging, chronic non…
A review of ginsenosides for skin issues like psoriasis and melanoma found the evidence is insufficient and absorption is low.
Frontiers Apr 24, 2026
Herring roe oil reduces inflammatory biomarkers in mild-to-moderate psoriasis
Dermatology RCT
Herring roe oil reduces inflammatory biomarkers in mild-to-moderate psoriasis Herring roe oil may lower inflammation in psoriasis
In a randomized controlled trial post hoc analysis of 64 patients with mild-to-moderate psoriasis, oral herring roe oil supplementation for …
A small trial found that herring roe oil reduced several blood-based inflammation markers in people with mild-to-moderate psoriasis over 26 …
medRxiv Apr 23, 2026
Secukinumab improves skin response in Chinese patients with psoriatic arthritis
Rheumatology Cohort
Secukinumab improves skin response in Chinese patients with psoriatic arthritis Secukinumab linked to skin improvement in Chinese psoriatic arthritis patients
This observational cohort study of 446 Chinese patients with psoriatic arthritis found that treatment with secukinumab for over 12 weeks was…
In Chinese psoriatic arthritis patients, secukinumab treatment was associated with significant skin improvement and better quality of life o…
Frontiers Apr 23, 2026
Autoimmune Thyroiditis Prevalence Higher in Obese Women With PCOS in Retrospective Cohort Analysis
OB/GYN & Women's Health Cohort
Autoimmune Thyroiditis Prevalence Higher in Obese Women With PCOS in Retrospective Cohort Analysis New PCOS Data Reveals Hidden Thyroid Risks
This retrospective cohort study evaluated 1,249 women with PCOS aged 18–44 years.
Women with PCOS should check their thyroid health regularly.
Frontiers Apr 22, 2026
MONO, ORM1, ORM2, and AGP levels show excellent diagnostic value for psoriasis identification in a retrospective case-control study
Dermatology Cohort
MONO, ORM1, ORM2, and AGP levels show excellent diagnostic value for psoriasis identification in a retrospective case-control study New Blood Test Could Spot Psoriasis Earlier, Study Suggests
This retrospective case-control study evaluated MONO, ORM1, ORM2, and AGP levels in 140 participants, including 70 patients with dermatology…
This research offers a new way to spot psoriasis risk early using a simple blood test, which could lead to faster treatment and better skin …
Frontiers Apr 22, 2026
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
Dermatology FDA Approval
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older The FDA has approved a new drug called Cosentyx for treating a serious skin condition
The FDA approved Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are c…
The FDA approved Cosentyx for moderate to severe plaque psoriasis in adults and children 6 and older.
FDA Apr 22, 2026
Case report describes secukinumab use in a woman with erythrodermic psoriasis and systemic capillary leak syndrome
Diabetes & Endocrinology Sys. Review
Case report describes secukinumab use in a woman with erythrodermic psoriasis and systemic capillary leak syndrome One case report links secukinumab to severe capillary leak syndrome in a woman with psoriasis
This case report details the clinical course of a 66-year-old woman with new-onset erythrodermic psoriasis who developed systemic capillary …
A woman with psoriasis developed life-threatening capillary leak syndrome after starting secukinumab, with symptoms improving only after sto…
Frontiers Apr 21, 2026
Review of cohort data finds AD linked to psoriasis risk and biologics associated with lower risk
Dermatology
Review of cohort data finds AD linked to psoriasis risk and biologics associated with lower risk Atopic Dermatitis Raises Psoriasis Risk, But Biologics Help
This narrative review synthesizes findings from a large cohort study.
A massive study shows that while eczema increases the chance of getting psoriasis, modern biologic drugs significantly protect against this …
medRxiv Apr 21, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Apr 21, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA has approved a new drug called Stelara for several inflammatory conditions
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
FDA Apr 21, 2026

Questions about Psoriasis

Are there regional differences in health issues for people with psoriasis?

Yes, regional differences exist in psoriasis-related health issues, including comorbidities, treatment patterns, and healthcare access, as shown by studies from North America, Europe, Asia, and Africa.

Full answer →
Is secukinumab effective for Chinese patients with psoriatic arthritis?

Yes, secukinumab is effective for Chinese patients with psoriatic arthritis, with real-world data and cost-effectiveness analyses supporting its use.

Full answer →